Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–3 of 3 results
Advanced filters: Author: Sandra G. Pasoto Clear advanced filters

  • Characterising the response to SARS-CoV-2 post vaccination is critical in the appraisement of the induced immune response, performance and protective potential. Here the authors present data from a phase 4 clinical trial in autoimmune rheumatic disease patients 6 months post second dose of Sinovac-CoronaVac inactivated vaccine that show a marked reduction in antibody particularly in males or those under treatment with immune targeting therapies but saw no rise in COVID-19 disease.

    • Clovis A. Silva
    • Ana C. Medeiros-Ribeiro
    • Eloisa Bonfa
    ResearchOpen Access
    Nature Communications
    Volume: 13, P: 1-9

  • In a large prospective phase 4 trial, vaccination with CoronaVac, an inactivated SARS-CoV-2 vaccine, elicited significantly lower virus-specific IgG antibodies and neutralizing antibodies in patients with autoimmune rheumatic diseases than in age- and sex-matched healthy control trial participants.

    • Ana C. Medeiros-Ribeiro
    • Nadia E. Aikawa
    • Eloisa Bonfa
    Research
    Nature Medicine
    Volume: 27, P: 1744-1751

  • In this Consensus Statement, an international group of experts and patient representatives validates and endorses the transition from the term ‘Sjögren syndrome’ to ‘Sjögren disease’, and issue several additional recommendations regarding the nomenclature of this disorder.

    • Manuel Ramos-Casals
    • Alan N. Baer
    • Arjan Vissink
    Reviews
    Nature Reviews Rheumatology
    Volume: 21, P: 426-437